Catheter Precision, Inc. (VTAK) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VTAK Revenue Growth
Revenue Breakdown (FY 2024)
VTAK's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
VTAK Revenue Analysis (2016–2024)
As of May 9, 2026, Catheter Precision, Inc. (VTAK) generated trailing twelve-month (TTM) revenue of $730,000, reflecting explosive growth of +135.4% year-over-year. The most recent quarter (Q3 2025) recorded $226,000 in revenue, up 6.6% sequentially.
Looking at the longer-term picture, VTAK's 5-year compound annual growth rate (CAGR) stands at -43.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $7.2 million in 2019.
Revenue diversification analysis shows VTAK's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ATRC (+15.0% YoY), IRTC (+27.4% YoY), and ELMD (+15.5% YoY), VTAK has outperformed the peer group in terms of revenue growth. Compare VTAK vs ATRC →
VTAK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VTAKCurrent | $730,000 | +135.4% | -43.4% | -2676.9% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 IRTC | $747M | +27.4% | +23.0% | -4.9% | |
 ELMD | $64M | +15.5% | +14.5% | 15.1% | |
 BSX | $20.1B | +19.9% | +15.2% | 19.8% |
VTAK Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $420K | -5.0% | $378K | 90.0% | $-11,243,000 | -2676.9% |
| 2023 | $442K | +3057.1% | $412K | 93.2% | $-78,119,000 | -17674.0% |
| 2022 | $14K | -36.4% | $-147,000 | -1050.0% | $-26,961,000 | -192578.6% |
| 2021 | $22K | -91.5% | $-1,538,000 | -6990.9% | $-29,266,000 | -133027.3% |
| 2020 | $259K | -96.4% | $-1,913,000 | -738.6% | $-35,401,000 | -13668.3% |
| 2019 | $7.2M | +15.1% | $-1,651,000 | -22.9% | $-57,730,000 | -801.9% |
| 2018 | $6.3M | +6.6% | $2.1M | 32.8% | $-31,160,000 | -498.0% |
| 2017 | $5.9M | -1.8% | $1.7M | 29.0% | $-17,760,000 | -302.6% |
| 2016 | $6.0M | - | $2.8M | 47.5% | $-4,198,000 | -70.2% |
See VTAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VTAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VTAK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVTAK — Frequently Asked Questions
Quick answers to the most common questions about buying VTAK stock.
Is VTAK's revenue growth accelerating or slowing?
VTAK revenue is accelerating at +135.4% year-over-year, exceeding the 5-year CAGR of -43.4%. TTM revenue reached $730000.00. Growth momentum has increased versus prior periods.
What is VTAK's long-term revenue growth rate?
Catheter Precision, Inc.'s 5-year revenue CAGR of -43.4% reflects the sustained expansion pattern. Current YoY growth of +135.4% is above this long-term average.
How is VTAK's revenue distributed by segment?
VTAK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.